- Previous Close
1.8180 - Open
1.7500 - Bid --
- Ask --
- Day's Range
1.6680 - 1.9000 - 52 Week Range
1.0700 - 7.5000 - Volume
254,637 - Avg. Volume
160,886 - Market Cap (intraday)
26.834M - Beta (5Y Monthly) -0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5900 - Earnings Date Oct 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.10
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
www.valbiotis.comRecent News: ALVAL.PA
View MorePerformance Overview: ALVAL.PA
Trailing total returns as of 8/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALVAL.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALVAL.PA
View MoreValuation Measures
Market Cap
26.83M
Enterprise Value
8.70M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.67
Price/Book (mrq)
1.37
Enterprise Value/Revenue
1.84
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-155.67%
Return on Assets (ttm)
-14.79%
Return on Equity (ttm)
-44.71%
Revenue (ttm)
4.73M
Net Income Avi to Common (ttm)
-7.37M
Diluted EPS (ttm)
-0.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
25.02M
Total Debt/Equity (mrq)
35.09%
Levered Free Cash Flow (ttm)
-5.56M